Cocrystal Q1, Updates on its Antiviral Drug-Development Programs

 

• Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024
• Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected in the second half of 2024
• FDA pre-IND feedback for oral CC-42344 received in first quarter of 2024 provides better clarity on late-stage trial design
• Initiation of Phase 1 study of inhaled CC-42344, a potential influenza treatment and post-exposure prophylactic, planned for the second half of 2024

https://www.globenewswire.com/news-release/2024/05/13/2880369/0/en/Cocrystal-Pharma-Reports-First-Quarter-2024-Financial-Results-and-Provides-Updates-on-its-Antiviral-Drug-Development-Programs.html